You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm will offer 4.7 million shares of its stock at $2.27 per share. Proceeds will go toward the development and commercialization of its tests.
The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.
A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.
The company has added three recently issued patents to the suit, filed Jan. 27, all covering methods for amplifying and sequencing nucleic acids.
Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
The firm recently published a study describing three assays for prostate cancer and reporting their sensitivity and specificity in case-control cohort.
Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 14 skipping alterations.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
The company announced an agreement with Piper Sandler & Co. to act as agent, creating an at-the-market equity program for up to $25 million in shares of its common stock.
The deal includes key testing services like Transplant's TruGraf blood test and Viracor's TRAC test, along with Viracor Eurofins' new SARS-CoV-2 test.
The reimbursement contract provides about 9 million additional men access to the urine-based, genomic EPI test, Bio-Techne said.
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
As part of the placement, the Singapore-based firm has issued almost 17.9 million new ordinary shares at an issue price of $.175 per share.
If the results are validated, investigators believe the method could help diagnose patients without the need for a needle biopsy and with fewer false positives.
The Belgian diagnostics company said it has partnered with Bristol-Myers Squibb to register its MSI test as a companion diagnostic in China.
The company expects that proceeds from this transaction, combined with another direct offering earlier this week and its current cash reserve, can support operations through the end of this year.
The firm has entered into a securities purchase agreement for the issuance and sale of 23 million shares of its common stock at $0.40 per share.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon reproductive health tests.